Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-synuclein-induced neuroinflammation refers to the inflammatory response in the central nervous system (CNS) triggered by the accumulation and aggregation of alpha-synuclein, a presynaptic neuronal protein. This process is central to the pathogenesis of Parkinson’s disease (PD) and other synucleinopathies. Alpha-synuclein aggregates are released from neurons into the extracellular space, where they interact with microglia, initiating a pro-inflammatory signaling cascade involving TLR2/TLR4, NF-κB, and the NLRP3 inflammasome, leading to the release of pro-inflammatory cytokines and subsequent neuronal death.
Modulation of inflammatory pathways; Inhibition of alpha-synuclein aggregation; Regulation of microglial activation; Enhancement of regulatory T cell function; Inhibition of cytokine production.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-synuclein induced Neuroinflammation.